The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Shahid Beheshti University of Medical Sciences

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Refractory Diabetic Macular Edema

Treatments: Drug: injection of bevacizumab; Drug: injection of bevacizumab and erythropoietin

Study type: Interventional

Funder types: Other

Identifiers

NCT03821168

95287

Details and patient eligibility

About

after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches.

In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.

Enrollment: 58 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patient with refractory diabetic macular edema at least one month after third injection

Exclusion criteria

• previous vitreoretinal surgery previous glaucoma surgery glaucomatous patient open heart surgery active proliferative diabetic retinopathy one eye patients vitreous hemorrhage

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

58 participants in 2 patient groups

intravitreal injection of bevacizumab and erythropoietin

Active Comparator group

Description:

erythropoietin:

Treatment:

Drug: injection of bevacizumab and erythropoietin

intravitreal injection of bevacizumab

Active Comparator group

Description:

bevacizumab:1.25 mg

Treatment:

Drug: injection of bevacizumab